Lasers in skin cancer prophylaxis

Expert Review of Anticancer Therapy

Volumn 8, Issue 11, 2008, Pages 1713-1717

  Halachmi, Shlomit ^a   Lapidoth, Moshe ^a  

^a RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; CARBON DIOXIDE; ERBIUM; FLUOROURACIL; IMIQUIMOD; NONSTEROID ANTIINFLAMMATORY AGENT; PORPHYRIN DERIVATIVE; PROTOPORPHYRIN; RETINOID DERIVATIVE; SUNSCREEN; TRICHLOROACETIC ACID;

ANTINEOPLASTIC ACTIVITY; AVOIDANCE BEHAVIOR; CANCER INHIBITION; CANCER PATIENT; CARBON DIOXIDE LASER; CLINICAL TRIAL; COST OF ILLNESS; DIODE LASER; EARLY DIAGNOSIS; EDITORIAL; ERBIUM YAG LASER; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; IMMUNOMODULATION; LASER SURGERY; LOW LEVEL LASER THERAPY; PHOTODYNAMIC THERAPY; SKIN CANCER; UNSPECIFIED SIDE EFFECT;

HUMANS; LASERS; SKIN NEOPLASMS;

EID: 60949097451     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.11.1713     Document Type: Editorial

References (57)

1. Bickers DR, Lim HW, Margolis D. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J. Am. Acad. Dermatol. 55(3), 490-500 (2006).
2. Glogau RG. The risk of progression to invasive disease. J. Am. Acad. Dermatol. 42(1 Pt 2), 23-24 (2000).
3. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 63 (8), 1727-1730 (2003).
4. Carlson JA, Scott D, Wharton J, Sell S. Incidental histopathologic patterns: possible evidence of 'field cancerization' surrounding skin tumors. Am. J. Dermatopathol. 23 (5), 494-496 (2001).
5. Kanjilal S, Strom SS, Clayman GL et al. p53 mutations in non-melanoma skin cancer of the head and neck: molecular evidence for field cancerization. Cancer Res. 55(16), 3604-3609 (1995).
6. Lebwohl M, Dinehart S, Whiting D et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two Phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J. Am. Acad. Dermatol. 50(5), 714-721 (2004).
7. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two Phase III, randomized, vehicle-controlled studies. J. Am. Acad. Dermatol. 50 (5), 722-733 (2004).
8. Tyring S, Conant M, Marini M, Van Der Meijden W, Washenik K. Imiquimod; an international update on therapeutic uses in dermatology. Int. J. Dermatol. 41(11), 810-816 (2002).
9. Schon M, Bong AB, Drewniok C et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J. Natl Canter Inst. 95(15), 1138-1149 (2003).
10. Ambach A, Bonnekoh B, Nguyen M, Schon MP, Gollnick H. Imiquimod, a Toll-like receptor-7 agonist, induces perform in cytotoxic Tlymphocytes in vitro. Mol. Immunol. 40(18), 1307-1314 (2004).
11. Davidovici BB, Tuzun Y, Wolf R. Retinoid receptors. Dermatol, Clin. 25(4), 525-530, viii (2007).
12. De Graaf YG, Euvrard S, Bouwes Bavinck JN. Systemic and topical retinoids in the management of skin cancer in organ transplant recipients. Dermatol. Surg. 30(4 Pt 2), 656-661 (2004).
13. Iraji F, Siadat AH, Asilian A, Enshaieh S, Shahmoradi Z. The safety of diclofenac for the management and treatment of actinic keratoses. Expert Opin. Drug Saf. 7(2), 167-172 (2008).
14. Ulrich C, Hackethal M, Ulrich M et al. Treatment of multiple actinic keratoses with topical diclofenac 3% gel in organ transplant recipients: a series of six cases. Br. J. Dermatol. 156(Suppl. 3) 40-42 (2007).
15. Nelson CG, Spencer J, Nelson CC Jr. A single-arm, open-label efficacy and tolerability study of diclofenac sodium 3% gel for the treatment of actinic keratosis of the upper and lower lip. J. Drugs Dermatal. 6(7), 712-717 (2007).
16. Weinberg JM. Topical therapy for actinic keratoses: current and evolving therapies. Rev. Recent Clin. Trials 1(1), 53-60 (2006).
17. Stockfleth E, Kerl H. Guidelines for the management of actinic keratoses. Eur. J. Dermatol. 16(6), 599-606 (2006).
18. Nelson C, Rigel, Smith, S, Swanson N, Wolf J. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze).J. Drugs Dermatol. 3(4), 401-407 (2004).
19. Hantash BM, Stewart DB, Coopd ZA, Rehmus WE, Koch RJ, Swetter SM. Facial resurfacing for non-melanoma skin cancer prophylaxis. Arch. Dermatol. 142(8), 976-982 (2006).
20. Witheiler DD, Lawrence N, Cox SE, Cruz C, Cockerell CJ, Freemen RG. Long-term efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Dermatol. Surg. 23(3), 191-196 (1997).
21. Trimas SJ, Ellis DA, Metz RD. The carbon dioxide laser. An alternative for the treatment of actinically damaged skin. Dermatol. Surg. 23(10), 885-889 (1997).
22. Massey RA, Eliezri YD. A case report of laser resurfacing as a skin cancer prophylaxis. Dermatol. Surg. 25(6), 513-516 (1999).
23. 2 lasers for prophylaxis of keratoses and cancers. Dermatol. Surg. 25(9), 729-732 (1999).
24. Field LM. The superiority of dermabrasion over laser abrasion in the prophylaxis of malignant and premalignant disease. Dermatol. Surg. 33(2), 258-259 (2007).
25. Iyer S, Friedli A, Bowes L, Kricorian G, Fitzpatrick RE. Full face laser resurfacing: therapy and prophylaxis for actinic keratoses and non-melanoma skin cancer. Lasers Surg. Med. 34(2), 114-119 (2004).
26. Ostertag JU, Quaedvlieg PJ, Neumann MH, Krekels GA. Recurrence rates and long-term follow-up after laser resurfacing as a treatment for widespread actinic keratoses on the face and scalp. Dermatol. Surg. 32(2), 261-267 (2006).
27. Orenstein A, Goldan O, Weissman O, Winkler E, Haik J. A new modality in the treatment of actinic cheilitis using the Er:YAG laser. J. Cosmet. Laser. Ther. 9 (1), 23-25 (2007).
28. Bodendorf MO, Grunewald S, Wetzig T, Simon JC, Paasch U. Fractional laser skin therapy. J. Dtsch Dermatol. Ges. (2008).
29. Alexiades-Armenakas MR, Dover JS, Arndt KA. The spectrum of laser skin resurfacing: nonablative, fractional, and ablative laser resurfacing. J. Am. Acad. Dermatol. 58(5), 719-737 (2008).
30. 2 laser rejuvenation. Lasers Surg. Med. 40(7), 454-460 (2008).
31. Lapidoth M, Yagima Odo ME, Odo LM. Novel use of erbium:YAG (2,940-nm) Laser for fractional ablative photothermolysis in the treatment of photodamaged facial skin: a pilot study. Dermatol. Surg. 34(8), 1048-1053 (2008).
32. Trelles MA, Velez M, Mordon S. Correlation of histological findings of single session Er:YAG skin fractional resurfacing with various passes and energies and the possible clinical implications. Lasers Surg. Med. 40(3), 171-177 (2008).
33. Cohen SR, Henssler C, Horton K, Broder KW. Moise-Broder PA. Clinical experience with the Fraxel SR laser: 202 treatments in 59 consecutive patients. Plast. Reconstr. Surg. 121(5), 297E-304E (2008).
34. Foster KW, Kouba DJ, Fincher EE et al. Early improvement in rhytides and skin laxity following treatment with a combination fractional laser emitting two wavelengths sequentiallyJ Drugs Dermatol. 7(2), 108-111 (2008).
35. Dierickx CC, Khatri KA, Tannous ZS et al. Micro-fractional ablative skin resurfacing with two novel erbium laser systems. Lasers Surg. Med. 40(2), 113-123 (2008).
36. Trelles MA, Mordon S, Velez M, Urdiales F, Levy JL. Results of fractional ablative facial skin resurfacing with the erbium:yttrium-aluminium-garnet laser 1 week and 2 months after one single treatment in 30 patients. Laser Med. Sci. DOI: 10-1007/ s10103-008-0545-3 (2008) (Epub ahead of print).
37. Graber EM, Tanzi EL, Alster TS. Side effects and complications of fractional laser photothermolysis: experience with 961 treatments. Dermatol. Surg. 34(3), 301-305 (2008).
38. Jih MH, Goldberg LH, Kimyai-Asadi A. Fractional photothermolysis for photoaging of hands. Dermatol. Surg. 34(1), 73-78 (2008).
39. 2 resurfacing of photoaged facial skin: preliminary clinical report. J. Cosmet. Laser Ther. 9(4), 218-225 (2007).
40. Alexiades-Armenakas M. Fractional laser resurfacing. J. Drugs Dermatol. 6(7), 750-751 (2007).
41. Collawn SS. Fraxel skin resurfacing. Ann. Plast. Surg. 58(3), 237-240 (2007).
42. Hantash BM, Bedi VP, Kapadia B et al. In vivo histological evaluation of a novel ablative fractional resurfacing device. Lasers Surg. Med. 39(2), 96-107 (2007).
43. Hantash BM, Bedi VP, Chan KF, Zachary CB. Ex vivo histological characterization of a novel ablative fractional resurfacing device. Lasers Surg. Med. 39(2), 87-95 (2007).
44. Geronemus RG. Fractional photothermolysis: current and future applications. Lasers Surg. Med. 38(3), 169-176 (2006).
45. Laubach HJ, Tannous Z, Anderson RR, Manstein D. Skin responses to fractional photothermolysis. Lasers Surg. Med. 38(2), 142-149 (2006).
46. Rostan EF. Laser treatment of photodamaged skin. Facial Plast. Surg. 21(2), 99-109 (2005).
47. Manstein D, Herron GS, Sink RK, Tanner H, Anderson RR. Aractional photothermolysis: a new concept for cutaneous remodeling using microscopic patterns of thermal injury. Lasers Surg. Med. 34(5), 426-438 (2004).
48. Chrastil B, Glaich AS, Goldberg LH, Friedman PM. Fractional photothermolysis: a novel treatment for disseminated superficial actinic porokeratosis. Arch. Dermatol. 143(11), 1450-1452 (2007).
49. Piaserico S, Belloni Fortina A, Rigorri P et al. Topical photodynamic therapy of actinic keratosis in renal transplant recipients. Transplant. Proc. 39(6), 1847-1850 (2007).
50. Marmur ES, Schmults CD, Goldberg DJ. A review of laser and photodynamic therapy for the treatment of non-melanoma skin cancer. Dermatol. Surg 30(2 Pt 2), 264-271 (2004).
51. Britton JE, Goulden V, Stables G, Stringer M, Shechan-Dare R. Investigation of the use of the pulsed dye laser in the treatment of Bowen's disease using 5-aminolaevulinic acid phototherapy. Br. J. Dermatol. 153 (4), 780-784 (2005).
52. Strasswimmer J, Grande DJ. Do pulsed lasers produce an effective photodynamic therapy response? Lasers Surg. Med. 38(1), 22-25 (2006).
53. Alexiades-Armenakas M. Laser-mediated photodynamic therapy. Clin. Dermatol. 24(1), 16-25 (2006).
54. Karrer S, Baumler W, Abels C, Hohenleutner U, Landthaler M, Szeimies RM. Long-pulse dye laser for photodynamic therapy: investigations in vitro and in vivo. Lasers Surg. Med. 25(1), 51-59 (1999).
55. Kelly KM, Kimel S, Smith T et al. Combined photodynamic and photothermal induced injury enhances damage to in vivo model blood vessels. Lasers Surg. Med. 34(5), 407-413 (2004).
56. Alexiades-Armenakas MR, Geronemus RG. Laser-mediated photodynamic the therapy of actinic cheilitis. J. Drugs Dermatol 3(5), 548-551(2004).
57. Ruiz-Rodriguez R, Lopez L, Candelas D, Zelickson B. Enhanced efficacy of photodynamic therapy after fractional resurfacing: fractional photodynamic rejuvenation. J. Drugs Dermatol. 6(8), 818-820 (2007).